Swiss pharmaceutical giant Novartis said Friday it planned to cut loose its Alcon eye care division, and aimed to buy back $5.0 billion of its own shares by the end of 2019.
Swiss pharmaceutical giant Novartis said Friday it planned to cut loose its Alcon eye care division, and aimed to buy back $5.0 billion of its own shares by the end of 2019.